UK markets open in 6 hours 26 minutes

NIKKEI 225
37,969.99
-490.09(-1.27%)
HANG SENG
17,201.27
+372.34(+2.21%)
CRUDE OIL
82.74
-0.07(-0.08%)
GOLD FUTURES
2,330.00
-8.40(-0.36%)
DOW
38,460.92
-42.77(-0.11%)
Bitcoin GBP
51,823.80
-1,562.76(-2.93%)

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Celltrion, Inc. (068270.KS)

KSE - KSE Delayed price. Currency in KRW

Add to watchlist

177,200.00

-2,300.00

(-1.28%)

As of 09:14AM KST. Market open.

Loading interactive chart…

Thomson Reuters StreetEvents
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call
PR Newswire
ZYMFENTRA™(infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab, now commercially available in the U.S.
Celltrion USA announced today the availability of a ZYMFENTRA™ (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab.[1] ZYMFENTRA is the first and only subcutaneous infliximab approved by the U.S. Food and Drug Administration (FDA) in 2023.
PR Newswire
Celltrion USA completes submission of Biologics License Application (BLA) to U.S. FDA for CT-P39, an interchangeable biosimilar candidate of XOLAIR® (omalizumab)
Celltrion USA today announced that the company has submitted a Biologics License Application (BLA) for CT-P39, an interchangeable biosimilar candidate to XOLAIR® (omalizumab) to the U.S. Food and Drug Administration (FDA).[1]